BCC 2021 | Reflecting on the use of CDK4/6 inhibitors in HR+ breast cancer
Giuseppe Curigliano, MD, PhD, University of Milan, Milan, Italy, outlines future directions in the treatment and management of patients with hormone receptor-positive (HR+) metastatic breast cancer, including how the results of the monarchE study (NCT03155997), a study of abemaciclib plus endocrine therapy in the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer, will shape the treatment of this patient population. This interview took place during the 17th St. Gallen International Breast Cancer Conference.
Disclosures
Dr. Curigliano reports personal fees from Roche, Pfizer, Novartis, Lilly, Foundation Medicine, BMS, Samsung, Astra Zeneca, Daichii Sankyo, Boeringer, GSK, Seagen, Roche, Novartis, Pfizer, Lilly, Foundation Medicine, Samsung, Daichii Sankyo, non-financial support from Roche, Pfizer, grants from Merck, and other from Ellipsis
